Mefloquine Prophylaxis in HIV-1 Individuals: a Randomized Placebo-controlled Trial

• Status: Completed
• Trial end date: 2011-05-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a randomized placebo controlled trial. Malaria chemoprophylaxis with mefloquine in asymptomatic HIV-infected adults living in a malaria endemic region of Luanshya, Zambia will be compared to a placebo control group and followed up for 18 months.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Institute of Tropical Medicine, Belgium
• Treatments: Mefloquine

Criteria

Inclusion Criteria:

• Permanent residents of the Luanshya district

• Males and non pregnant adults between 18 and 50 years old.

• Having a CD4 cell count of least 350 perµL at enrolment

• HIV sero-status determined at the VCT of the health center.

• No obvious underlying disease at time of enrolment

• Signed informed consent

Exclusion Criteria:

• HIV stage III or IV following the WHO classification (see attached documents regarding policy in Zambia)

• Evidence of underlying chronic diseases (cardiac, renal, hepatic, malnutrition, TB).

• Intent to move out of the study catchment area during the study period

• History of allergy to MQ (or related drugs) or sulfa drugs

• Chorionic gonadotrophic hormone in urine or obvious pregnancy